Skip to main content

Advertisement

SpringerLink
Log in

Imprecise risk estimation of chemotherapy-related cardiotoxicity in HER2-positive breast cancer using the recently reported societal risk tools

  • Letter to the Editor
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability

Not applicable.

References

  1. Lyon AR, Dent S, Stanway S et al (2020) Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 22:1945–1960

    Article  Google Scholar 

  2. Battisti NML, Andres MS, Lee KA et al (2021) Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer. Breast Cancer Res Treat 188:149–163

    Article  CAS  Google Scholar 

  3. Ozcelik C, Erdmann B, Pilz B et al (2002) Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A 99:8880–8885

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors wish to acknowledge the support of the National Breast Cancer Institute, Cancer Managed Clinical and Academic Networks (MCANs), and the Precision Cardio-Oncology Enterprise (P-CORE).

Funding

None.

Author information

Authors and Affiliations

  1. Disciplines of Cardiology and Surgical Oncology, Saolta Group, Health Service Executive and CORRIB Core Lab, Galway University Hospital, National University of Ireland Galway (NUIG), Galway, H91 TK33, Ireland

    Osama Soliman, Aoife Lowery & Michael Kerin

Authors
  1. Osama Soliman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aoife Lowery
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Kerin
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

On behalf of the Precision Cardio-Oncology Enterprise (P-CORE) Investigators

Contributions

OS, AL, and MK conceived and wrote the paper.

Corresponding author

Correspondence to Osama Soliman.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

Not applicable.

Informed consent

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Soliman, O., Lowery, A., Kerin, M. et al. Imprecise risk estimation of chemotherapy-related cardiotoxicity in HER2-positive breast cancer using the recently reported societal risk tools. Breast Cancer Res Treat 190, 355–356 (2021). https://doi.org/10.1007/s10549-021-06403-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-021-06403-4

Search

Navigation